Penclomedine | CAS# 108030-77-9 | Antineoplastic Agent

MedKoo Cat#: 564339 | Name: Penclomedine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Penclomedine is an antineoplastic agent which alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.

Chemical Structure

Penclomedine

CAS#108030-77-9

Theoretical Analysis

MedKoo Cat#: 564339

Name: Penclomedine

CAS#: 108030-77-9

Chemical Formula: C8H6Cl5NO2

Exact Mass: 322.8841

Molecular Weight: 325.39

Elemental Analysis: C, 29.53; H, 1.86; Cl, 54.47; N, 4.30; O, 9.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

NSC-338720; NSC 338720; NSC338720; Penclomedine

IUPAC/Chemical Name

3,5-Dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine

InChi Key

DZVPGIORVGSQMC-UHFFFAOYSA-N

InChi Code

InChI=1S/C8H6Cl5NO2/c1-15-5-3(9)6(8(11,12)13)14-7(16-2)4(5)10/h1-2H3

SMILES Code

ClC(C1=C(Cl)C(OC)=C(Cl)C(OC)=N1)(Cl)Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 325.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: de Smidt PC, Campanero MA, Trocóniz IF. Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility. Int J Pharm. 2004 Feb 11;270(1-2):109-18. PubMed PMID: 14726127. 2: O'Reilly S, O'Hearn E, Struck RF, Rowinsky EK, Molliver ME. The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum. Invest New Drugs. 2003 Aug;21(3):269-79. PubMed PMID: 14578677. 3: Tiwari A, Waud W, Struck R. Determination of the phamacophore of penclomedine, a clinically-evaluated antitumor pyridine derivative. Bioorg Med Chem. 2002 Nov;10(11):3593-8. PubMed PMID: 12213474. 4: Liu G, Berlin J, Tutsch KD, Van Ummersen L, Dresen A, Marnocha R, Arzomanian R, Alberti D, Feierabend C, Binger K, Wilding G. Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy. Clin Cancer Res. 2002 Mar;8(3):706-11. PubMed PMID: 11895899. 5: Tiwari A, Riordan JM, Waud WR, Struck RF. Synthesis and antitumor activity of several new analogues of penclomedine and its metabolites. J Med Chem. 2002 Feb 28;45(5):1079-85. PubMed PMID: 11855988. 6: O'Reilly S, Hartman NR, Bowling KM, Rowinsky EK, Donehower RC, Collins J, Strong JM. Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine. Cancer Chemother Pharmacol. 2001 Sep;48(3):223-8. PubMed PMID: 11592344. 7: Struck RF, Tiwari A, Friedman HS, Keir S, Morgan LR, Waud WR. Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine. Cancer Chemother Pharmacol. 2001 Jul;48(1):47-52. PubMed PMID: 11488524. 8: Rakovitch E, Mellado W, Hall EJ, Sawant SG, Geard CR, Newman RA, Pandita TK. Penclomedine-induced DNA fragmentation and p53 accumulation correlate with reproductive cell death in colorectal carcinoma cells with altered p53 status. Oncol Rep. 1999 Jan-Feb;6(1):161-5. PubMed PMID: 9864421. 9: Hartman NR, Leo KU, Brewer TG, Strong JM. The in vitro metabolism of penclomedine in mouse, rat, and human systems. Drug Metab Dispos. 1998 Jun;26(6):513-9. PubMed PMID: 9616185. 10: Jodrell DI, Bowman A, Stewart M, Dunlop N, French R, MacLellan A, Cummings J, Smyth JF. Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously. Br J Cancer. 1998 Mar;77(5):808-11. PubMed PMID: 9514062; PubMed Central PMCID: PMC2149952.